GRAIL, Inc. (NASDAQ: GRAL) Investor Alert: Deadline in Lawsuit on August 4, 2026

A deadline is coming up on August 4, 2026in the lawsuit filed for certain investors of GRAIL, Inc. (NASDAQ: GRAL) over alleged securities laws violations by GRAIL, Inc.

Investors who purchased shares of GRAIL, Inc. (NASDAQ: GRAL) have certain options and there are strict and short deadlines running. Deadline: August 4, 2026. NASDAQ: GRAL stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Menlo Park, CA based GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. According to the complaint, one of Grail's Galleri trials was the "NHS-Galleri trial," the primary objective of which was "to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test compared with those who did not."
GRAIL, Inc. (NASDAQ: GRAL) reported that its annual Total Revenue rose from $125.59 million in 2024 to $147.17 million in 2025, and that its Net Loss declined from over $2.02 billion in 2024 to $408.35 million in 2025.

On February 19, 2026, GRAIL, Inc announced that "primary endpoint of statistically significant Stage III-IV reduction was not observed" in the NHS-Galleri Trial. Grail allegedly attributed this shortcoming, in part, on "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately."

Shares of GRAIL, Inc. (NASDAQ: GRAL) declined from $118.84 per share on January 22, 2026, to as low as $41.50 per share on February 23, 2026.

According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of GRAIL, Inc. (NASDAQ: GRAL) common shares between May 13, 2025 and February 19, 2026, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 13, 2025 and February 19, 2026, the defendants made false and/or misleading statements and/or failed to disclose that the defendants created the false impression that they possessed reliable information pertaining to the probability of achieving the primary endpoint of a statistically significant reduction in Stage III-IV cancers in Grail's NHS-Galleri trial, while also concealing material adverse facts which reduced the possibility of such an outcome;, that in truth, Grail's optimism in achieving the primary endpoint of its NHS-Galleri study fell short of reality, and that the confidence management provided in light of the "Positive Top-Line Results" from the trial's first screening round and the Pathfinder studies was misplaced and ignored potential trendlines in unreleased topline data and other information learned since the inception of the study that suggested three years would be less sufficient than previously thought to demonstrate the achievability of the primary endpoint.

Those who purchased shares of GRAIL, Inc. (NASDAQ: GRAL) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.